Skip to main content
Porto

Main navigation

  • Home
  • PMMNG Meetings
    • PMMNG Monthly Meetings
    • Steering Committee Meetings
  • Myeloma Events
  • Our Members
  • Miles for Myeloma 5K
  • Diversity & Inclusion
  • Resources
    • Myeloma Education Resources
    • Myeloma and Cancer Foundations
    • Regional Myeloma Support Groups
    • Publications and Newsletters
    • Cancer Support Networks
    • Treatments
    • Financial Assistance
    • Caregivers
  • Clinical Trials

News Menu

  • Miles for Myeloma 5K Registration Is Open
  • Cindy Chmielewski Interviews Dr. Francesco Maura at ASH 2021
  • PMMNG Member Survey Results
  • Celebrating the Martin Luther King Jr. Day of Service
  • Celgene Class Action Lawsuit Settlement
  • Face Masks Are Available
  • Financial Toxicity Survey for Myeloma Patients
  • Covid-19 Emergency Financial Aid for Cancer Patients
  • HealthTree COVID-19 Myeloma Patient Study and Antibody Test
  • OncoLink Survey of Covid-19 Impacts to Cancer Patients
  • 2020 Miles for Myeloma Will Be a Virtual Race
  • Maddie Hunter to Host Patient Power - UAMS Web Program
Revlimid
From myelomacrowd.org

PMMNG member Phil Falkowitz started taking Revlimid (lenalidomide) way back in 2001, during the Phase 1 clinical trial of Revlimid. That trial went well for him (and for Revlimid). Phil's experience related to the clinical trial is described in a recent Journal of Clinical Research Best Practices article. Phil still takes Revlimid, and now has been taking it the second longest of anyone in the world.

Tags
news
clinical trial
Revlimid
lenalidomide
Phil Falkowitz